DE3783541D1 - Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen. - Google Patents

Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.

Info

Publication number
DE3783541D1
DE3783541D1 DE8787901815T DE3783541T DE3783541D1 DE 3783541 D1 DE3783541 D1 DE 3783541D1 DE 8787901815 T DE8787901815 T DE 8787901815T DE 3783541 T DE3783541 T DE 3783541T DE 3783541 D1 DE3783541 D1 DE 3783541D1
Authority
DE
Germany
Prior art keywords
compositions
locally applying
msh analogs
applying alpha
stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787901815T
Other languages
English (en)
Other versions
DE3783541T2 (de
Inventor
J Hruby
E Hadley
Robert Dorr
Norman Levine
Elizabeth Sugg
Wayne L Cody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Competitive Technologies Inc
Original Assignee
University Patents Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Patents Inc filed Critical University Patents Inc
Application granted granted Critical
Publication of DE3783541D1 publication Critical patent/DE3783541D1/de
Publication of DE3783541T2 publication Critical patent/DE3783541T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8787901815T 1986-02-03 1987-01-23 Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen. Expired - Lifetime DE3783541T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82516286A 1986-02-03 1986-02-03
PCT/US1987/000226 WO1987004623A1 (en) 1986-02-03 1987-01-23 Method of stimulating melanocytes by topical application of analogs of alpha-msh, and compositions for use in same

Publications (2)

Publication Number Publication Date
DE3783541D1 true DE3783541D1 (de) 1993-02-25
DE3783541T2 DE3783541T2 (de) 1993-06-17

Family

ID=25243274

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787901815T Expired - Lifetime DE3783541T2 (de) 1986-02-03 1987-01-23 Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.

Country Status (11)

Country Link
US (2) US4918055A (de)
EP (1) EP0259440B1 (de)
KR (1) KR900005903B1 (de)
AT (1) ATE84420T1 (de)
AU (1) AU597630B2 (de)
CA (1) CA1282324C (de)
DE (1) DE3783541T2 (de)
DK (1) DK518187A (de)
IE (1) IE60883B1 (de)
NZ (1) NZ233248A (de)
WO (1) WO1987004623A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2711549B2 (ja) * 1987-06-01 1998-02-10 圭吉 杉山 白髪防止・改善用組成物
US5049547A (en) * 1988-02-11 1991-09-17 University Patents, Inc. Composition for stimulating integumental melanocytes
US4874744A (en) * 1989-03-13 1989-10-17 University Of Cincinnati Method of using melanocyte stimulating hormone as dermatis treatment
EP0389950A1 (de) * 1989-03-23 1990-10-03 Lion Corporation Inhibitor des melanocytenstimulierenden Hormons und dieses enthaltendes, äusserlich anwendbares Präparat
US5470577A (en) * 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5420109A (en) 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
FR2733421B1 (fr) * 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US5767152A (en) * 1995-05-04 1998-06-16 Nielsen; Thor Bagger Composition and methods for stimulating hair growth
GB9801191D0 (en) * 1998-01-20 1998-03-18 Unilever Plc Skin and hair darkening composition
US6696417B1 (en) 1997-11-21 2004-02-24 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin and hair darkening composition
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
JP2002534968A (ja) * 1999-01-22 2002-10-22 ザ スキーペンズ アイ リサーチ インスティテュート インコーポレイテッド α−メラニン細胞刺激ホルモンによる調節Ｔ細胞の活性化
US6800291B1 (en) * 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
JP4767418B2 (ja) * 1999-03-24 2011-09-07 エムエスエイチ ファーマ，インコーポレイテッド アルファ−メラノサイト−刺激ホルモン由来の抗菌性アミノ酸配列
US7402559B2 (en) 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
WO2002006316A2 (en) * 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
NZ534450A (en) * 2002-02-26 2008-08-29 Arizona Board Of Regents Of Be Method of stimulation of melanin production and induction of skin tanning comprising administering alpha-MSH and exposing skin to UV irradiation
DE10228837B4 (de) * 2002-06-27 2016-01-07 Elfriede Rauch Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel
EP1689349B9 (de) 2003-11-24 2014-02-26 Clinuvel Pharmaceuticals Limited Verfahren zur induktion der melanogenese bei menschen mit mc1r varianten allelen
CA2575866C (en) * 2004-08-04 2018-07-10 Clinuvel Pharmaceuticals Limited Methods for inducing melanogenesis in a subject
EP2939686A1 (de) 2004-10-08 2015-11-04 Clinuvel Pharmaceuticals Limited Zusammensetzungen und verfahren zur induzierung von melanogenese in ein subjekt
US7910101B2 (en) 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
JP2008518026A (ja) 2004-10-27 2008-05-29 ユニバーシティ・オブ・デンバー 副腎皮質刺激ホルモンアナログおよびこれに関連する方法
WO2008015342A2 (fr) * 2006-08-03 2008-02-07 Societe D'extraction Des Principes Actifs Sa (Vincience) Utilisation d'un extrait vegetal en tant qu'agent actif pour augmenter la synthese de melanine dans les melanocytes
EP2056854A4 (de) * 2006-08-28 2011-09-14 Clinuvel Pharmaceuticals Ltd Verfahren zur reduzierung der inzidenz oder rate der entstehung von hautkrebs und verwandter erkrankungen
PT2865422T (pt) * 2006-08-31 2017-11-14 Clinuvel Pharmaceuticals Ltd Derivados de alfa-msh para o tratamento de fotodermatoses
JP2010505580A (ja) * 2006-10-13 2010-02-25 リライアンス ライフ サイエンシーズ ピーヴィーティー． リミテッド 生体高分子上での培養メラニン細胞
CA2719707C (en) * 2008-03-27 2018-12-04 Clinuvel Pharmaceuticals Limited Therapy for vitiligo
EP2350031A2 (de) 2008-08-20 2011-08-03 Ensemble Therapeutics Corporation Makrocyclische verbindungen zur inhibierung des tumornekrosefaktors alpha
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013135880A1 (en) * 2012-03-15 2013-09-19 Galderma Research & Development Combination of a mc1r receptor agonist and uvb for the treatment and/or prevention of pigmentation disorders
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US20140271742A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Skin tanning using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
WO2015063102A1 (en) 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in bullous disease
WO2015063099A1 (en) 2013-10-28 2015-05-07 Clinuvel Ag Alpha-msh analogues for use in the treatment of hailey-hailey disease
WO2015067503A1 (en) 2013-11-07 2015-05-14 Clinuvel Ag Alpha-msh analogues for use in the treatment of psoriasis
EP3197920B1 (de) 2014-09-25 2021-01-13 Nanyang Technological University Targeting von melanozyten zur abgabe therapeutischer oder diagnostischer wirkstoffe unter verwendung von proteinnanokäfigen
US20170304406A1 (en) 2014-10-28 2017-10-26 Clinuvel Ag New indication for alpha-msh analogues
US20170360896A1 (en) 2014-10-28 2017-12-21 Clinuvel Ag Inflammatory disease
WO2016195476A1 (en) 2015-05-29 2016-12-08 Erasmus University Medical Center Rotterdam Treatment of cardiac arrhythmias
CN106265134B (zh) * 2016-03-17 2019-02-19 哈尔滨源茂达生物技术有限公司 一种多肽美白修复精华液及其制备方法
EP3573645B1 (de) 2017-02-01 2024-03-13 Vallaurix Mc S.A.R.L. Alpha-msh-analoga zur behandlung von xeroderma pigmentosum

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2158123A1 (de) * 1970-12-02 1972-06-08 Ciba-Geigy Ag, Basel (Schweiz) Neue pharmazeutische Präparate
US4457864A (en) * 1981-10-23 1984-07-03 University Patents, Inc. Synthetic analogues of α-melanotropin
US4485039A (en) * 1982-06-11 1984-11-27 University Patents, Inc. Synthetic analogues of α-melanotropin
DE3623019A1 (de) * 1986-07-09 1988-01-21 Dieter Prof Dr Dr Aderhold Melanotropin als therapeutischer wirkstoff

Also Published As

Publication number Publication date
NZ233248A (en) 1993-01-27
EP0259440A1 (de) 1988-03-16
AU7082887A (en) 1987-08-25
DK518187A (da) 1987-12-02
EP0259440B1 (de) 1993-01-13
ATE84420T1 (de) 1993-01-15
EP0259440A4 (de) 1989-11-07
DE3783541T2 (de) 1993-06-17
IE870236L (en) 1987-08-03
WO1987004623A1 (en) 1987-08-13
IE60883B1 (en) 1994-08-24
US4866038A (en) 1989-09-12
US4918055A (en) 1990-04-17
KR900005903B1 (ko) 1990-08-16
DK518187D0 (da) 1987-10-02
AU597630B2 (en) 1990-06-07
CA1282324C (en) 1991-04-02
KR880700670A (ko) 1988-04-11

Similar Documents

Publication Publication Date Title
DE3783541D1 (de) Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
DE3871297D1 (de) Zusammensetzung sowie verfahren zum niederschlagen von loetmittel.
DE68918943D1 (de) Gewebeentzusammensetzung und verfahren.
DE68919637D1 (de) Verfahren und Einrichtung zur Sprachsynthese durch Überdeckung und Summierung von Wellenformen.
DE3782917D1 (de) Verfahren zum herabsetzen des gehalts an rueckstaendigen aldehyden in implantierbaren bioprosthetischen geweben.
DE3671858D1 (de) Verfahren zur herstellung von verbundplatten.
DE3888205D1 (de) Verfahren zur behandlung von lungenaffektionen und zubereitungen dafür.
DE58901193D1 (de) Verfahren zum mischen sowie zugehoerige mischvorrichtung.
DE3579218D1 (de) Verfahren und geraet fuer die behandlung von blutbestandteilen.
DK90888A (da) Maaleapparat til vaevsmetabolisme
AT381025B (de) Verfahren zur herstellung von topischen pharmazeutischen zubereitungen
DE3579886D1 (de) Kosmetikum um das altern der haut zu verzoegern und verfahren zu dessen anwendung.
DE69001248D1 (de) Verfahren und zusammensetzungen zur isolation von menschlichem relaxin.
AT374846B (de) Herzstueck, insbesondere herzstueckspitze, fuer schienenkreuzungen oder -weichen, sowie verfahren zu seiner herstellung
DE3775826D1 (de) Fluessige zusammensetzung fuer aesthetische hautbehandlung und verfahren zu deren herstellung.
DE59707400D1 (de) Beschichtete, mechanisch beanspruchbare Komponenten oder Elemente sowie Verfahren zum Herstellen von solchen Komponenten oder Elementen
KR880701018A (ko) 우물 자체 정렬 및 이온 이식 마스킹용의 이중층 포로레지스트 처리 방법
DE69100811D1 (de) Verfahren zur behandlung von einer wässerigen lösung, die insbesondere salpetersäure und flusssäure enthält.
DE3770224D1 (de) Verfahren zur herstellung von hypofluoriten und bis-hypofluoriten.
DE3688168D1 (de) Epidermiszellenextrakte und verfahren zur verbesserung der wundheilung und zur regenerierung der epidermis.
AR223346A1 (es) Un conjunto sujetador de rieles de clavar de ferrocarril,una abrazadera y un asiento de aplicacion en dicho conjunto
DE3574974D1 (de) Verfahren zur herstellung von milbemycinderivaten und einige in diesem verfahren verwendete derivate.
DE3677833D1 (de) Verfahren zur herstellung von omega-isocyanatoalkyl(meth)acrylaten.
DE3582542D1 (de) Verfahren zur expressionsverbesserung und mittel hierfuer.
NO874962D0 (no) Totrinnsmetode for indolent saarheling og vandig medium og topisk salve benyttet i denne forbindelse.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: COMPETITIVE TECHNOLOGIES, INC. (N.D.GES.D. STAATES